Get the Stockscreener App
30.01
0.66%
-0.20
After Hours:
30.01
Xoma Royalty Corp stock is traded at $30.01, with a volume of 21,608.
It is down -0.66% in the last 24 hours and up +2.07% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
See More
Previous Close:
$30.21
Open:
$30.39
24h Volume:
21,608
Relative Volume:
0.89
Market Cap:
$355.72M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-11.16
EPS:
-2.69
Net Cash Flow:
$-14.79M
1W Performance:
-3.69%
1M Performance:
+2.07%
6M Performance:
+17.64%
1Y Performance:
+87.91%
1-Day Range:
$29.50
$31.08
1-Week Range:
$29.09
$32.50
52-Week Range:
$14.33
$33.78
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| XOMA | 30.01 | 355.72M | 9.71M | -29.96M | -14.79M | -2.69 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
Short Interest in XOMA Co. (NASDAQ:XOMA) Drops By 23.5% - Defense World
XOMA Co. (NASDAQ:XOMA) Sees Large Decrease in Short Interest - MarketBeat
Xoma royalty corp CFO Thomas Burns sells shares worth $292,663 By Investing.com - Investing.com Australia
Xoma CEO Owen Hughes sells $655,335 in stock - Investing.com India
Xoma royalty corp CFO Thomas Burns sells shares worth $292,663 - Investing.com
What Makes XOMA Royalty (XOMA) a New Buy Stock - Yahoo Finance
XOMA Royalty Reports Third Quarter 2024 Financial Results and Recent Activities - Defense World
What is HC Wainwright's Forecast for XOMA FY2025 Earnings? - MarketBeat
XOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
XOMA Royalty Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
XOMA Royalty’s Third Quarter 2024 Financial Insights - TipRanks
XOMA Royalty: Q3 Earnings Snapshot - CT Insider
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities - ForexTV.com
Xoma reports Q3 EPS ($1.59), consensus (44c) - TipRanks
XOMA Royalty Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
XOMA Reports Mixed Q3: FDA Approval Win Despite $17.2M Loss, Expands Portfolio | XOMA Stock News - StockTitan
XOMA stock soars to 52-week high, reaching $32 By Investing.com - Investing.com UK
XOMA stock soars to 52-week high, reaching $32 - Investing.com
XOMA (NASDAQ:XOMA) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
XOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
XOMA Royalty Corporation's (NASDAQ:XOMA) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week - Simply Wall St
XOMA stock soars to 52-week high, reaching $30.7 By Investing.com - Investing.com South Africa
XOMA stock soars to 52-week high, reaching $30.7 - Investing.com India
XOMA’s (XOMA) Buy Rating Reaffirmed at HC Wainwright - Defense World
XOMA Co. (NASDAQ:XOMAO) Short Interest Down 40.0% in October - Defense World
Twist Bioscience enters into purchase agreement with XOMA Royalty - MSN
XOMA (NASDAQ:XOMA) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
XOMA Royalty Corporation Acquires 50% of Twist's Existing Royalty and Milestone Economics for $15 Million - Marketscreener.com
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience - The Manila Times
XOMA Royalty Significantly Expands its Royalty and - GlobeNewswire
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash - The Bakersfield Californian
Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year - Yahoo Finance
Ellsworth Advisors LLC Makes New $516,000 Investment in XOMA Co. (NASDAQ:XOMA) - MarketBeat
XOMA stock soars to 52-week high, reaching $30.49 - Investing.com
XOMA stock soars to 52-week high, reaching $30.49 By Investing.com - Investing.com South Africa
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties (NASDAQ:XOMA) - Seeking Alpha
XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
XOMA Co. (NASDAQ:XOMA) is Stonepine Capital Management LLC’s 6th Largest Position - Defense World
PIMCO Strategic Income Fund, XOMA Corporation, Another 2 Companies Have A High Estimated Dividend Yield - Via News Agency
Rhumbline Advisers Raises Stock Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average of $25.91 - Defense World
XOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average of $25.91 - MarketBeat
XOMA Co. (NASDAQ:XOMAO) Announces $0.52 Quarterly Dividend - Defense World
XOMA shares hold as analyst reiterates Buy rating post-FDA nod - Investing.com
XOMA Royalty gains FDA-approved asset for NPC By Investing.com - Investing.com Canada
XOMA Royalty gains FDA-approved asset for NPC - Investing.com
XOMAOXOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock Latest Stock News & Market Updates - StockTitan
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. - GlobeNewswire
Xoma notes FDA approval of Zevra’s MIPLYFFA in patients with NPC - TipRanks
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):